TNDM - Tandem Diabetes Care Inc. Investors: Lead Plaintiff Deadline is Approaching in the Class Action Against Tandem Diabetes Care Inc.; Contact Robbins LLP Today | Benzinga
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Tandem Diabetes Care, Inc. (NASDAQ:TNDM) securities between August 3, 2022 and November 2, 2022. Tandem is a global medical technology company that develops, manufactures, and markets a variety of consumer technologies and software for at-home diabetes care.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: Tandem Diabetes Care, Inc. (TNDM) Misled Investors Regarding Revenue Projections
According to the complaint, defendants provided investors with material information concerning Tandem's projected revenue and sales for the year ending 2022. Specifically, on August 2, 2022, Tandem estimated annual sales "to be in the range of $835 million to $845 million, which represents an annual growth of 19 percent to 20 percent ...